NCT01382199Unknown3 期
A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
Ventria Bioscience0 个研究点目标入组 340 人开始时间: 2011年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 340
- 主要终点
- Reduction in the number of days of antibiotic associated diarrhea during the treatment period
研究概览
简要总结
The purpose of the study is to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients must meet all of the inclusion criteria listed below at the time of enrollment.
- •Male and female patients 50 years of age and older.
- •Resident of a participating long term care facility.
- •Able to consume 30 mL of liquid solution two time per day by mouth or enteral feeding tube.
- •Patient has had no antibiotics in the 4 weeks preceding enrollment in the study.
- •Patient has been started on a broad spectrum antibiotic(s) for an infection other than gastroenteritis.
- •Patient has a life expectancy greater than 6 months.
- •Patient or health care agent is able and willing to sign a written informed consent.
- •Patient or caregiver is able and willing to complete diary of daily bowel movement information (number, formed or unformed, time) during any portion of the 8 week study.
排除标准
- •Patient has an ileostomy.
- •Patient has a prior history of major gastrointestinal surgery such as partial small bowel or colon resection or gastric bypass.
- •Patient has a history of inflammatory bowel disease.
- •Patient has a history of chronic diarrhea associated with irritable bowel syndrome or other etiologies.
- •Patient has a history of severe constipation requiring use of enemas or disimpaction within 30 days prior to enrollment.
- •Patient has signs or symptoms of C. difficile infection including diarrhea.
- •Patient has signs or symptoms of acute or chronic diarrhea.
- •Patient has known sensitivity or allergy to rice or rice products.
- •Patient has significant medical problems which in the judgment of the principal investigator or medical monitor may interfere with participation in the study.
- •Patient is not receiving an antibiotic regimen consisting of a broad spectrum antibiotic.
- •Patient has participated in an investigational study using an investigational product within 30 days of randomization.
研究组 & 干预措施
Ven100
Experimental
Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
干预措施: Lactoferrin (Drug)
结局指标
主要结局
Reduction in the number of days of antibiotic associated diarrhea during the treatment period
次要结局
未报告次要终点
研究者
相似试验
撤回
1 期
A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. EpidermidisStaphylococcal InfectionsBacteremiaNCT00509847AM-Pharma
已完成
2 期
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell CarcinomaCarcinoma, Renal CellNCT00095186Agennix40
暂停
2 期
Safety and Efficacy of Talactoferrin Alfa in Patients With Severe SepsisSevere SepsisNCT01273779Agennix1,280
已完成
2 期
Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe SepsisSevere SepsisNCT00630656Agennix190
Unknown
不适用
Use of Recombinant Human Lactoferrin in Long-Term Care Patients With Feeding Tubes With Clostridium Difficile.Clostridium DifficileNCT00377078Johns Hopkins University30